-transparent.png){kind=logo}
Amikacin was administered to 18 patients with gram-negative septicemia. Ten of the patients had blood culture isolates highly resistant to gentamicin; six of these patients had persistent bacteremia while receiving gentamicin alone or in combination with other agents. Fourteen of the 18 patients were cured with amikacin therapy and adjunctive measures. Nine of the 10 patients with gentamicin-resistant pathogens were cured. The occurrence of nephrotoxicity in four patients with elevated amikacin serum levels and serious underlying disease indicates the desirability of monitoring serum amikacin levels. Minor ototoxicity occurred in two patients and was associated with prolonged therapy and high serum amikacin levels. Amikacin is a highly effective agent for treating patients with gram-negative bacteremia; it is the agent of choice in the therapy of patients with suspected or documented gram-negative bacteremia caused by pathogens resistant to gentamicin and susceptible to amikacin.
R D Meyer, and
R P Lewis, and
S M Finegold
February 1977,
JAMA,
R D Meyer, and
R P Lewis, and
S M Finegold
June 1977,
The American journal of medicine,
R D Meyer, and
R P Lewis, and
S M Finegold
April 1970,
Canadian Medical Association journal,
R D Meyer, and
R P Lewis, and
S M Finegold
May 1966,
Naika. Internal medicine,
R D Meyer, and
R P Lewis, and
S M Finegold
December 1964,
Military medicine,
R D Meyer, and
R P Lewis, and
S M Finegold
June 1975,
The Japanese journal of antibiotics,
R D Meyer, and
R P Lewis, and
S M Finegold
January 1977,
Nihon rinsho. Japanese journal of clinical medicine,
R D Meyer, and
R P Lewis, and
S M Finegold
January 1972,
La Nouvelle presse medicale,
R D Meyer, and
R P Lewis, and
S M Finegold
June 1982,
Revue medicale de Bruxelles,
R D Meyer, and
R P Lewis, and
S M Finegold
January 1964,
Transactions of the American Association of Genito-Urinary Surgeons,
